Compare CURR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | RCEL |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 226 |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.6M | 132.0M |
| IPO Year | N/A | N/A |
| Metric | CURR | RCEL |
|---|---|---|
| Price | $2.61 | $4.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | 108.1K | ★ 214.9K |
| Earning Date | 04-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $21.69 |
| Revenue Next Year | $14.56 | $49.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $3.22 |
| 52 Week High | $4.68 | $10.28 |
| Indicator | CURR | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 74.69 | 39.13 |
| Support Level | $1.44 | $3.98 |
| Resistance Level | $4.68 | $4.09 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | 0.02 | -0.13 |
| Stochastic Oscillator | 92.86 | 12.60 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.